IN2014CN03762A - - Google Patents

Info

Publication number
IN2014CN03762A
IN2014CN03762A IN3762CHN2014A IN2014CN03762A IN 2014CN03762 A IN2014CN03762 A IN 2014CN03762A IN 3762CHN2014 A IN3762CHN2014 A IN 3762CHN2014A IN 2014CN03762 A IN2014CN03762 A IN 2014CN03762A
Authority
IN
India
Prior art keywords
attachment
please see
please
see
Prior art date
Application number
Inventor
Jean-Luc Girardet
Yung-Hyo Koh
La Rosa Martha De
Esmir Gunic
Zhi Hong
Stanley Lang
Hongwoo Kim
Original Assignee
Ardea Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ardea Biosciences Inc filed Critical Ardea Biosciences Inc
Publication of IN2014CN03762A publication Critical patent/IN2014CN03762A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Road Signs Or Road Markings (AREA)
  • Pens And Brushes (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Please see the attachment
IN3762CHN2014 2004-08-25 2005-08-25 IN2014CN03762A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US60422004P 2004-08-25 2004-08-25
US60421904P 2004-08-25 2004-08-25
US68635105P 2005-05-31 2005-05-31
PCT/US2005/030259 WO2006026356A2 (en) 2004-08-25 2005-08-25 S-TRIAZOLYL α-MERCAPTOACETANILDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE

Publications (1)

Publication Number Publication Date
IN2014CN03762A true IN2014CN03762A (en) 2015-09-25

Family

ID=36000576

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3762CHN2014 IN2014CN03762A (en) 2004-08-25 2005-08-25

Country Status (32)

Country Link
US (8) US7947721B2 (en)
EP (5) EP2135608B8 (en)
JP (2) JP4952943B2 (en)
KR (1) KR101241716B1 (en)
CN (2) CN101083987B (en)
AT (2) ATE528001T1 (en)
AU (2) AU2005280130C9 (en)
BR (2) BRPI0520870B8 (en)
CA (1) CA2578068C (en)
CY (2) CY1112221T1 (en)
DK (1) DK2135608T3 (en)
EA (2) EA014737B1 (en)
EC (1) ECSP077322A (en)
ES (2) ES2374773T3 (en)
FR (1) FR16C0031I2 (en)
HK (1) HK1133582A1 (en)
HR (1) HRP20130075T1 (en)
HU (1) HUS1600034I1 (en)
IL (3) IL181523A (en)
IN (1) IN2014CN03762A (en)
LT (1) LTC2135608I2 (en)
LU (1) LU93169I2 (en)
ME (1) ME01512B (en)
MX (1) MX2007002236A (en)
NL (1) NL300825I2 (en)
NZ (2) NZ553534A (en)
PL (1) PL2135608T3 (en)
PT (1) PT2135608E (en)
RS (1) RS52632B (en)
SG (2) SG185992A1 (en)
SI (1) SI2135608T1 (en)
WO (1) WO2006026356A2 (en)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2135608T3 (en) * 2004-08-25 2012-01-23 Ardea Biosciences Inc S-triazolyl-alpha-mercaptoacetanilides as inhibitors of HIV reverse transcriptase
WO2007050087A1 (en) 2004-08-25 2007-05-03 Ardea Biosciences, Inc. N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
EP2155692B1 (en) 2007-05-30 2015-06-17 F. Hoffmann-La Roche AG Non-nucleoside reverse transcriptase inhibitors
WO2009030996A1 (en) * 2007-09-05 2009-03-12 Coley Pharmaceutical Group, Inc. Triazole compounds as toll-like receptor (tlr) agonists
US8084483B2 (en) * 2007-11-27 2011-12-27 Ardea Biosciences, Inc. Compounds and compositions and methods of use
CA2735828C (en) * 2008-09-04 2013-07-23 Esmir Gunic Substituted-(naphthalen-1-yl)-1h-imidazoles and their use for modulating uric acid levels
US8173690B2 (en) 2008-09-04 2012-05-08 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
US8242154B2 (en) 2008-09-04 2012-08-14 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
WO2010048592A1 (en) * 2008-10-24 2010-04-29 Ardea Biosciences, Inc. Compositions comprising 4- (2- ( 5-br0m0-4- ( 1-cyclopropylnaphthalen-4-yl) -4h-1, 2, 4-triaz0l-3-ylthi0) acetamido -3-chlorobenzoic acid and pharmaceutically acceptable salts thereof
AR073964A1 (en) * 2008-10-24 2010-12-15 Ardea Biosciences Inc COMPOSITIONS INCLUDING ACID 4- (2- (5-BROMO-4- (1-CICLOPROPILNAFTALEN -4-IL) -4H- 1,2,4-TRIAZOL-3-IL TIO) ACETAMIDE) -3-CHLOROBENZOIC AND ITS SALTS PHARMACEUTICALLY ACCEPTABLE AND METHODS OF PREPARATION AND USE OF THE SAME
US8372807B2 (en) 2009-05-20 2013-02-12 Ardea Biosciences, Inc. Methods of modulating uric acid levels
CN102040546B (en) * 2009-10-10 2014-10-15 台州市华南医化有限公司 Preparation method of 4-cyclopropyl-1-naphthaline isothiocyanate and intermediate 4-cyclopropyl-1-naphthaldehyde oxime/halide
AU2011203708B2 (en) * 2010-01-08 2013-08-01 Ardea Biosciences, Inc. Polymorphic, crystalline and mesophase forms of sodium 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetate, and uses thereof
US9402827B2 (en) 2010-03-30 2016-08-02 Ardea Biosciences, Inc. Treatment of gout
EP2582683B1 (en) 2010-06-15 2018-03-21 Ardea Biosciences, Inc. Treatment of gout and hyperuricemia
CN102939279B (en) 2010-06-16 2014-07-16 亚德生化公司 Phenylthioacetate compounds, compositions and methods of use
AR081930A1 (en) 2010-06-16 2012-10-31 Ardea Biosciences Inc THIOACETATE COMPOUNDS
CN101899013B (en) * 2010-07-12 2012-07-25 山东大学 2-(2-substituted aryl-2H-1,2,4-triazole-3-sulfydryl) acetamide derivative and preparation method and application thereof
EP2627331A4 (en) * 2010-10-15 2014-03-12 Ardea Biosciences Inc Methods for treating hyperuricemia and related diseases
US8546436B2 (en) 2010-12-30 2013-10-01 Ardea Biosciences, Inc. Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and uses thereof
DK2776028T3 (en) 2011-11-03 2019-02-04 Ardea Biosciences Inc 3,4-DISUBSTITUTED PYRIDIDE COMPOUND, PROCEDURES FOR USING IT AND COMPOSITIONS INCLUDING THIS
AR091651A1 (en) * 2012-07-03 2015-02-18 Ardea Biosciences Inc ACID ELABORATION 2- (5-BROMO-4- (4-CICLOPROPILNAFTALEN-1-IL) -4H-1,2,4-TRIAZOL-3-ILTIO) ACETIC
CN105263913B (en) * 2013-06-14 2017-12-15 广东东阳光药业有限公司 Thio 1,2,4 triazole derivative and preparation method thereof
CN103524440B (en) * 2013-10-15 2015-09-09 苏州鹏旭医药科技有限公司 The preparation method of gout therapertics Lesinurad and Lesinurad intermediate
EP3071554B1 (en) * 2013-11-22 2018-10-03 Crystal Pharmatech Co., Ltd. Crystalline forms of lesinurad
CN104557748A (en) * 2014-01-25 2015-04-29 广东东阳光药业有限公司 Novel solid form of sulpho-1,2,4-triazole derivative
CN105315218A (en) * 2014-07-17 2016-02-10 天津药物研究院 Preparation method of lesinurad intermediate namely 1-naphthyltriazole thioketone
CN104341363B (en) * 2014-10-27 2016-08-17 张远强 A kind of nitro substituted triazole sulphonyl malonic acid compounds, Preparation Method And The Use
CN104370842B (en) * 2014-10-27 2016-07-13 张远强 The triazole sulphonyl malonic acid compounds of phenyl replacement, Preparation Method And The Use
CN104326993B (en) * 2014-10-27 2016-08-17 张远强 A kind of nitro substituted 1,2,4-triazole sulfenyl malonic acid compounds, Preparation Method And The Use
CN104341362B (en) * 2014-10-27 2016-07-13 张远强 Triazole sulphonyl malonic acid compounds, Preparation Method And The Use
CN104326998B (en) * 2014-10-27 2016-08-17 张远强 Phenyl substituted triazole malonic acid compounds, Preparation Method And The Use
CN104341361B (en) * 2014-10-27 2017-01-11 张远强 Cyano-substituted triazolesulfonylmalonic acid compounds as well as preparation method and application thereof
CN104327000B (en) * 2014-10-27 2016-08-17 张远强 Phenyl substituted triazole sulfenyl malonic acid compounds, Preparation Method And The Use
CN104370841B (en) * 2014-10-27 2016-07-13 张远强 Triazole sulfenyl malonic acid compounds, Preparation Method And The Use
CN104311498B (en) * 2014-10-27 2016-04-06 张远强 Triazole sulphonyl propanedioic acid compounds, Preparation Method And The Use that alkoxyl group replaces
EP3112334A1 (en) 2015-06-29 2017-01-04 DPx Fine Chemicals Austria GmbH & CoKG Process for manufacturing 1-cyclopropyl-naphthalenes
CN104987311A (en) * 2015-06-30 2015-10-21 安徽万邦医药科技有限公司 Preparing method for (4-(4-cyclopropyl-naphthalene-1-yl)-5-nitr-4H-(1, 2, 4) triazole-3-ylsulfanyl)-ethyl acetate and intermediate (5-nitr-4H-(1, 2, 4) triazole-3-sulfenyl)-ethyl acetate thereof
CN105153056A (en) * 2015-07-01 2015-12-16 安徽万邦医药科技有限公司 New preparation method of [5-bromo-4-(4-cyclopropyl-naphthalene-1-yl)-4H-[1, 2, 4]triazole-3-ylthioalkyl]-methyl acetate
CN105017168A (en) * 2015-07-01 2015-11-04 安徽万邦医药科技有限公司 New preparation method of [5-bromo-4-(4-cyclopropyl-naphthalene-1-yl)-4H-[1, 2, 4]triazole-3-ylsulfanyl]-methyl acetate
WO2017036884A1 (en) 2015-08-28 2017-03-09 Sandoz Ag A lesinurad, free form / lesinurad ethyl ester co-crystal
CN105566237B (en) * 2016-03-01 2018-05-18 山东大学 A kind of preparation method for the triazole mercapto phenylacetic acid compound for treating gout
ES2931470T3 (en) 2016-06-17 2022-12-29 Medshine Discovery Inc Halogenated compound and axially chiral isomer thereof
EP3281941B1 (en) 2016-08-11 2019-07-24 Zentiva K.S. Process for preparing 2-(5-bromo-4-(1-cyclopropylnaphthalen-4-yl)-4h-1,2,4-triazol-3-ylthio)acetic acid
EP3372592A1 (en) 2017-03-07 2018-09-12 Zentiva, k.s. Solid forms of lesinurad amine salts
US10351537B2 (en) * 2017-03-10 2019-07-16 Apotex Inc. Processes for the preparation of lesinurad and intermediates thereof
EP3315494A1 (en) 2017-04-19 2018-05-02 Química Sintética, S.A. Amorphous form of lesinurad and processes for its preparation
CN108947919B (en) 2017-05-17 2023-05-02 上海奥博生物医药股份有限公司 Novel preparation method of anti-gout drug Lesinurad and key intermediate thereof
WO2019001325A1 (en) * 2017-06-28 2019-01-03 苏州科睿思制药有限公司 Crystal form xv of lesinurad and preparation method therefor
EP3498697A1 (en) 2017-12-12 2019-06-19 Química Sintética, S.A. Novel salts and polymorphs of lesinurad
JPWO2022249788A1 (en) 2021-05-28 2022-12-01

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2008A (en) * 1841-03-18 Gas-lamp eok conducting gas pkom ah elevated buhner to one below it
US2006A (en) * 1841-03-16 Clamp for crimping leather
US2009A (en) * 1841-03-18 Improvement in machines for boring war-rockets
US226186A (en) 1880-04-06 Car-coupling
JPS5641637B2 (en) 1973-11-26 1981-09-29
US6832996B2 (en) * 1995-06-07 2004-12-21 Arthrocare Corporation Electrosurgical systems and methods for treating tissue
JPH07215940A (en) 1994-01-27 1995-08-15 Torii Yakuhin Kk Compound having antiviral activity
AU6144098A (en) 1997-02-14 1998-09-08 Bayer Corporation Amide derivatives as selective neuropeptide y receptor antagonists
US6245817B1 (en) * 1997-02-14 2001-06-12 Bayer Corporation NPY5 receptor antagonists and methods for using same
JPH10243033A (en) * 1997-02-28 1998-09-11 Oki Electric Ind Co Ltd Demodulator
DE69943247D1 (en) * 1998-03-27 2011-04-14 Janssen Pharmaceutica Nv HIV-inhibiting pyrimidine derivatives
NZ511267A (en) 1998-11-12 2002-12-20 Neurocrine Biosciences Inc Tricyclic heterocyclic CRF receptor antagonists and their use in treatment
US6414147B1 (en) * 1998-12-23 2002-07-02 Neurogen Corporation 2-amino-9-alkylpurines: GABA brain receptor ligands
DE69939749D1 (en) * 1998-12-25 2008-11-27 Shionogi & Co AROMATIC HETEROCYCLES WITH HIV INTEGRASE INHIBITING PROPERTIES
US6593077B2 (en) * 1999-03-22 2003-07-15 Special Materials Research And Technology, Inc. Method of making thin films dielectrics using a process for room temperature wet chemical growth of SiO based oxides on a substrate
CA2439820A1 (en) 2001-03-02 2002-09-12 Smithkline Beecham Corporation Benzophenones as inhibitors of reverse transcriptase
JO3429B1 (en) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv Hiv inhibiting pyrimidines derivatives
US7229987B2 (en) 2002-05-13 2007-06-12 Eli Lilly And Company Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes
EP2353593B1 (en) 2002-08-23 2012-08-22 Ardea Biosciences, Inc. Non-nucleoside reverse transcriptase inhibitors
US7642277B2 (en) 2002-12-04 2010-01-05 Boehringer Ingelheim International Gmbh Non-nucleoside reverse transcriptase inhibitors
PL227577B1 (en) 2003-02-07 2017-12-29 Janssen Pharmaceutica Nv Pyrimidine derivatives for the prevention of hiv infection
US8026245B2 (en) 2003-09-25 2011-09-27 Janssen Pharmaceutica N.V. HIV replication inhibiting purine derivatives
US20080031901A1 (en) * 2004-09-24 2008-02-07 Abbott Laboratories Sustained release monoeximic formulations of opioid and nonopioid analgesics
US7517998B2 (en) 2004-06-01 2009-04-14 Boehringer Ingelheim International Gmbh Non nucleoside reverse transcriptase inhibitors
DK2135608T3 (en) 2004-08-25 2012-01-23 Ardea Biosciences Inc S-triazolyl-alpha-mercaptoacetanilides as inhibitors of HIV reverse transcriptase
WO2007050087A1 (en) 2004-08-25 2007-05-03 Ardea Biosciences, Inc. N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
US8084483B2 (en) * 2007-11-27 2011-12-27 Ardea Biosciences, Inc. Compounds and compositions and methods of use
WO2010048592A1 (en) 2008-10-24 2010-04-29 Ardea Biosciences, Inc. Compositions comprising 4- (2- ( 5-br0m0-4- ( 1-cyclopropylnaphthalen-4-yl) -4h-1, 2, 4-triaz0l-3-ylthi0) acetamido -3-chlorobenzoic acid and pharmaceutically acceptable salts thereof
AR073964A1 (en) 2008-10-24 2010-12-15 Ardea Biosciences Inc COMPOSITIONS INCLUDING ACID 4- (2- (5-BROMO-4- (1-CICLOPROPILNAFTALEN -4-IL) -4H- 1,2,4-TRIAZOL-3-IL TIO) ACETAMIDE) -3-CHLOROBENZOIC AND ITS SALTS PHARMACEUTICALLY ACCEPTABLE AND METHODS OF PREPARATION AND USE OF THE SAME
TWM377707U (en) 2009-09-16 2010-04-01 Nat Energy Technology Co Ltd Assembly of power supply

Also Published As

Publication number Publication date
IL181523A (en) 2013-12-31
ECSP077322A (en) 2007-04-26
CN101083987B (en) 2011-01-26
HK1133582A1 (en) 2010-04-01
CN101817793A (en) 2010-09-01
NZ553534A (en) 2010-10-29
EP1789039A2 (en) 2007-05-30
AU2009217458B2 (en) 2009-11-19
CN101083987A (en) 2007-12-05
EP2402011A1 (en) 2012-01-04
BRPI0520870B8 (en) 2021-05-25
CY2016028I1 (en) 2016-12-14
SG185992A1 (en) 2012-12-28
EP2135608A1 (en) 2009-12-23
IL181523A0 (en) 2007-07-04
US20080176850A1 (en) 2008-07-24
BRPI0520870B1 (en) 2020-11-10
US20180002296A1 (en) 2018-01-04
WO2006026356A2 (en) 2006-03-09
US8252828B2 (en) 2012-08-28
AU2005280130C1 (en) 2010-02-18
KR20070054694A (en) 2007-05-29
JP4952943B2 (en) 2012-06-13
US8003681B2 (en) 2011-08-23
EP2135608B1 (en) 2011-10-12
BRPI0514630B1 (en) 2020-09-15
SI2135608T1 (en) 2012-03-30
NL300825I2 (en) 2017-01-24
RS52632B (en) 2013-06-28
PT2135608E (en) 2012-01-13
US20100267724A2 (en) 2010-10-21
US20110190491A1 (en) 2011-08-04
ATE540677T1 (en) 2012-01-15
JP5457472B2 (en) 2014-04-02
KR101241716B1 (en) 2013-03-08
NZ581376A (en) 2011-05-27
ME01512B (en) 2014-04-20
IL219131A0 (en) 2012-06-28
JP2012077088A (en) 2012-04-19
EP2135608B8 (en) 2012-03-21
AU2005280130A1 (en) 2006-03-09
EA014737B1 (en) 2011-02-28
AU2009217458A1 (en) 2009-10-15
LTPA2016024I1 (en) 2016-09-12
FR16C0031I1 (en) 2016-09-23
SG155246A1 (en) 2009-09-30
LU93169I2 (en) 2016-10-10
US20150094284A1 (en) 2015-04-02
EP2433633A1 (en) 2012-03-28
US8946273B2 (en) 2015-02-03
US20120283301A1 (en) 2012-11-08
US20100069645A1 (en) 2010-03-18
WO2006026356A3 (en) 2006-08-10
CY1112221T1 (en) 2015-12-09
US20110313157A1 (en) 2011-12-22
BRPI0514630B8 (en) 2021-05-25
AU2005280130B2 (en) 2009-09-10
FR16C0031I2 (en) 2017-03-31
CA2578068C (en) 2011-08-09
CY2016028I2 (en) 2016-12-14
ATE528001T1 (en) 2011-10-15
ES2380604T3 (en) 2012-05-16
IL201546A (en) 2013-10-31
EA200700488A1 (en) 2007-08-31
US20100081827A1 (en) 2010-04-01
US8481581B2 (en) 2013-07-09
MX2007002236A (en) 2007-07-09
EA015846B1 (en) 2011-12-30
LTC2135608I2 (en) 2017-07-25
JP2008510828A (en) 2008-04-10
EA200901186A1 (en) 2010-04-30
HRP20130075T1 (en) 2013-02-28
CA2578068A1 (en) 2006-03-09
US7947721B2 (en) 2011-05-24
EP1789039A4 (en) 2009-08-05
EP2402011B1 (en) 2012-11-14
EP1789039B1 (en) 2012-01-11
DK2135608T3 (en) 2012-01-23
AU2005280130C9 (en) 2010-03-04
CN101817793B (en) 2014-01-08
HUS1600034I1 (en) 2016-09-28
AU2009217458A8 (en) 2009-10-29
EP2609917A1 (en) 2013-07-03
BRPI0514630A (en) 2008-06-17
PL2135608T3 (en) 2012-07-31
ES2374773T3 (en) 2012-02-21

Similar Documents

Publication Publication Date Title
IN2014CN03762A (en)
IN2014CN03629A (en)
IN2012DN02610A (en)
SG155211A1 (en) Peptide
TWI365550B (en) Illumination source
SG149831A1 (en) Benzimidazole derivatives
ZAA200500621S (en) Earphone
GB2430762B (en) Light source arrangement
IN2014CN04215A (en)
GB0400537D0 (en) Le beanock/the beanock
MD2731B2 (en)
TWM259667U (en) Simple-type fixture
AU305367S (en) Shower base
GB0400945D0 (en) The bugcap
GB2411464B (en) Diffuser
CA107672S (en) Dispenser holder
HK1069723A2 (en) Faraday flashlight.
PL115148U1 (en) Chandelier
AU306341S (en) Entertainment unit
AU306760S (en) Entertainment unit
AU305007S (en) Entertainment unit
AU302487S (en) Entertainment unit
AU302484S (en) Entertainment unit
AU305697S (en) Desk
AU302525S (en) Design 1 - 5 light - lighting fixture